Single-use bioreactors market seen reaching $16.28 billion by 2030

The Business Research Company says the global single-use bioreactors market will grow from $7.5 billion in 2026 to $16.28 billion by 2030, led by rising demand for biopharmaceutical production, vaccines and cost-effective manufacturing. North America held the largest share in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Single-use bioreactors are gaining traction because biopharmaceutical manufacturers want faster production, lower contamination risk and more flexible scaling. - The market’s projected jump to $16.28 billion by 2030 signals continued investment in disposable bioprocessing systems across drug, vaccine and biologics manufacturing. - A larger market could accelerate the shift away from traditional stainless steel systems in facilities built for speed and adaptability.

What happened: - The Business Research Company released a market report projecting the global single-use bioreactors market will rise from $7.5 billion in 2026 to $16.28 billion by 2030. - The report estimates a 21.4% compound annual growth rate during the forecast period. - The company also pegged the market at $6.18 billion in 2025, before expansion to $7.5 billion in 2026. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - Single-use bioreactors use a disposable bag instead of a conventional culture vessel. - The design supports disposable technologies in production steps that historically relied on stainless steel equipment. - The setup is intended to speed bioprocessing, simplify workflows and reduce contamination risk. - Growth drivers include rising biopharmaceutical research, wider monoclonal antibody production, expanding clinical trial pipelines and demand for rapid bioprocess development. - The forecast period also reflects higher investment in biologics manufacturing, broader use of continuous bioprocessing, more demand for vaccine production and a stronger focus on cost-effective biomanufacturing. - The report points to growing use of disposable bioprocessing technologies, flexible and scalable bioreactor systems, single-use systems in bioproduction, modular biomanufacturing facilities and contamination-reduction efforts. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The report offers a free sample and the full market report.

Between the lines: - The report frames pharmaceutical demand as the main commercial engine for the market. - That demand is tied to broader disease burden, which is pushing more drug consumption and healthcare use worldwide. - The citation of Italy’s 2023 medicine consumption data is meant to reinforce the scale of pharmaceutical demand supporting the market outlook. - The emphasis on modular facilities and continuous processing suggests buyers want manufacturing systems that can adapt more quickly to changing product pipelines.

What's next: - The market’s next phase will likely hinge on biologics capacity additions, vaccine production needs and continued adoption of disposable systems. - Asia-Pacific’s expected growth could narrow the gap with North America if investment and manufacturing expansion continue. - Manufacturers and investors will likely watch contamination control, scale flexibility and cost reduction as the main competitive differentiators.

The bottom line: - Single-use bioreactors are moving from a niche manufacturing option to a core bioprocessing platform, and the market forecast points to sustained global expansion through 2030.